Biosensor Platform Provides Protein Results in 10 Minutes
The BioTools Innovator winner aims to displace traditional ELISA testing by utilizing existing real-time PCR hardware.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Would you use an at-home diagnostic platform to monitor your protein biomarkers from your phone?
eGlint, Inc. won the BioTools Innovator program Capstone Event, securing $250,000 in prize money. The company has developed a biosensor platform that detects protein biomarkers in 10 minutes using existing real-time PCR infrastructure.
Why it matters
The platform aims to reduce the time and complexity of protein detection by matching the sensitivity of standard ELISA tests with a faster, more accessible workflow. By leveraging existing lab hardware, the technology accelerates diagnostic testing cycles within clinical and manufacturing environments.
The eGlint platform utilizes aptamers—DNA or RNA molecules that bind to specific targets—tagged with a fluorophore and a quencher to detect proteins. It achieves a 10-minute turnaround by engineering beads in solution to increase the mixing rate for biomarker capture.
The players
eGlint, Inc.
A biotech startup specializing in aptamer-based biosensor platforms for protein detection in clinical and manufacturing settings.
BioTools Innovator
An industry program that identifies and supports emerging life science tools companies through pitch competitions and mentorship.
The details
The platform uses aptamer-based biosensors to detect proteins in serum samples. When a target biomarker binds to the aptamer, the signal-blocking quencher separates from the signal-emitting fluorophore, creating a detectable light output. By using engineered beads in solution, the system ensures rapid target contact. The method is designed to function on standard real-time PCR (polymerase chain reaction) machines, which are widely used to amplify and detect DNA sequences.
Timeline
2021: eGlint, Inc. was founded.
October 14, 2026: The company won the BioTools Innovator pitch finals.
Q1 2027: The company plans to launch its first process-monitoring panel.
The Tech Race
The platform competes directly with traditional ELISA kits that dominate protein quantification in research and clinical workflows. By repurposing the existing real-time PCR machine install base, eGlint avoids the need for dedicated, specialized detection hardware.
Biopharmaceutical companies currently testing these aptamer-based kits in clinical trials can expect a commercial process-monitoring panel by early Q1 2027. The platform is designed to integrate into existing laboratory workflows, requiring only access to standard real-time PCR machines.
The takeaway
eGlint offers a path to faster protein detection by leveraging widely deployed PCR infrastructure. Stakeholders should monitor the company's planned product launch in Q1 2027 to see if the technology meets the stated performance metrics at scale.
Further reading
For broader trends in rapid diagnostic platforms and laboratory innovation, see the Biotech section.
Source note: This article includes information reported by The Scientist.
Live Poll
Would you use an at-home diagnostic platform to monitor your protein biomarkers from your phone?
